Levodopa in the treatment of Parkinson's disease: current controversies. - Wikidata - wikimedia - TriplyDB

Levodopa in the treatment of Parkinson's disease: current controversies.

Levodopa in the treatment of Parkinson's disease: current controversies.

http://www.wikidata.org/entity/Q35889917

about

The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors Intrastriatal Grafting of Chromospheres: Survival and Functional Effects in the 6-OHDA Rat Model of Parkinson's Disease Role of Different Alpha-Synuclein Strains in Synucleinopathies, Similarities with other Neurodegenerative Diseases Fuzzy Decision Making Approach to Identify Optimum Enzyme Targets and Drug Dosage for Remedying Presynaptic Dopamine Deficiency Dopamine signaling is essential for precise rates of locomotion by C. elegans.Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia.Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease.Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.Pramipexole for the treatment of early Parkinson's disease.Glycyrrhetinic acid and E.resveratroloside act as potential plant derived compounds against dopamine receptor D3 for Parkinson's disease: a pharmacoinformatics study.Rotigotine transdermal patch in Parkinson's disease: a systematic review and meta-analysis.Presynaptic effects of levodopa and their possible role in dyskinesia.Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease Low-dose levodopa protects nerve cells from oxidative stress and up-regulates expression of pCREB and CD39 Present and future drug treatment for Parkinson's disease.How to optimize the treatment of early stage Parkinson's disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease.Simultaneous estimation of levodopa, carbidopa and 3-oxymethyldopa in rat plasma using HPLC-ECD.Selegiline orally disintegrating tablets for the treatment of Parkinson's disease.Parkinson's disease management strategies.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.Adenosine A2A Receptor Blockade Prevents Rotenone-Induced Motor Impairment in a Rat Model of Parkinsonism.Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.Treatment of Parkinson's disease in the advanced stage.Autosomal dominant Parkinson's disease and the route to new therapies.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside.Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion.Protection against Parkinson's disease progression: clinical experience.In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias.Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons Levodopa medication improves incidental sequence learning in Parkinson's disease.Pathogenesis-targeted, disease-modifying therapies in Parkinson disease.

P2860

Q24605294-87846DDC-7CD2-4040-A9B5-17BB3BC48503 Q24657515-8414220D-5C1F-4964-9D43-99A6B486190D Q27329815-B2093526-1DDF-42ED-A864-0FFF4FA6B31A Q28082714-4BC39E5A-AB5C-4EBB-9C1E-601C36939AEA Q28554723-EA4A981B-F738-4016-B046-3C07F619F530 Q31066332-E2280D47-3D17-4A02-AB0D-189714F5A10E Q33255884-2EF5260D-2637-4DA7-93FB-59213A7B039D Q33260250-B20AFD39-DD84-46C7-AC61-F5DD501C2B0C Q33989482-5098A4BA-DD5C-49F4-AA6A-63117BBA2FE6 Q34044620-E9B0E953-C5D9-4FEB-9CD7-0C7AB18BA003 Q34504316-A49926E9-FCF7-4A43-B38E-8EF435CA751E Q34512544-D6A341BE-04AB-48DE-A6B3-75F520C7E03E Q34630735-FADAFCF3-E42D-40CE-A9B1-D80AF74256A7 Q34770959-CC829BF0-A6E3-4464-A2D5-92E2266BF7F0 Q34921068-96AC6715-44E2-4D18-AA01-B26EE30AE5F8 Q35040280-E88CB392-4ED8-464E-8386-7E9C55040069 Q35106629-804C2916-18BB-44C6-BED0-728FD6B78D3C Q35152033-03DB8826-71F2-4EFE-8903-1F4EB4D05BAC Q35484805-BD99058B-34F3-4B47-A728-4B4F2B558899 Q35599297-E0FB5A93-E655-4863-943D-A33A1F0DC4AA Q35614156-53892A8A-8C54-466E-8769-CE4E980D7786 Q35885133-8DAA337C-560D-4202-95D9-7E15F552A712 Q35934083-0097A1E0-A2F1-4697-A437-CFB7FDA825C2 Q36307839-5195964D-A838-401B-AD79-875F645CEFD1 Q36390875-9B9644EC-2194-4344-B753-F65AE0440678 Q36499640-CCEB71C7-196E-4D6B-A00B-646AF2D96F68 Q36521884-B4C3E473-2F7A-4051-90DD-1CA102F126A8 Q36627429-AB861C4D-C4F2-4695-A8EA-1ED0D14C773A Q36641474-99E8EFC1-CC26-4712-8382-E4F809E8FA0B Q36725292-14E11E95-4C53-4D9E-9C47-1141CC78E054 Q36847250-7ED5D689-8702-4A56-B241-8B2B7CB408ED Q36866618-1DDDE5B7-17AB-4F7F-A115-6FA102D9B222 Q36910602-7D296570-8AA2-4C7F-95F0-D58F079B4465 Q37021321-68AEC930-47DB-4934-9344-153494DF62B0 Q37086136-4D666ACD-70E4-4230-A5D2-47783D594F07 Q37131239-E86A3D49-1DC9-4B84-94DC-0CBBA2EA9DDF Q37173272-E8B5283F-209D-44B1-8137-4803681A99F4 Q37180671-8B1A8102-5601-4767-8513-027C507398E1 Q37502519-96EB78ED-3741-43E6-B4C5-87D392F45F92 Q37506492-F830DC5A-CFF9-47BB-A397-27253C76C8C6

P2860

Levodopa in the treatment of Parkinson's disease: current controversies.

http://www.wikidata.org/entity/Q35889917

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

2004年论文

@zh

2004年论文

@zh-cn

name

Levodopa in the treatment of Parkinson's disease: current controversies.

@ast

Levodopa in the treatment of Parkinson's disease: current controversies.

@en

type

label

Levodopa in the treatment of Parkinson's disease: current controversies.

@ast

Levodopa in the treatment of Parkinson's disease: current controversies.

@en

prefLabel

Levodopa in the treatment of Parkinson's disease: current controversies.

@ast

Levodopa in the treatment of Parkinson's disease: current controversies.

@en

P1433

Q35889917-C1E8FDF5-5B68-47FF-8E3A-AD66CBBA1EB0

P1476

Q35889917-A324AD51-DE52-40F4-BD98-DE1F1A3CE90A

P2093

Q35889917-0F3F7EB7-979A-413C-B6D7-68DF09DDE08D

Q35889917-188F1253-683E-4DE7-9361-2E085BCDE4ED

Q35889917-26943EAB-AA69-4B50-A386-AFA337C1A17B

Q35889917-4D0A8E69-EF8B-464E-8F9A-4C87B0138766

Q35889917-5002EB62-B0F2-44D2-9F4E-623F3123BCB5

Q35889917-589A6258-15FD-4A9D-87BF-9B993388FE33

Q35889917-5BD9AB6D-CC80-4D10-9367-9611699C7FBD

Q35889917-842D0D9A-45AF-4CE2-AC00-731DBFAC3F67

Q35889917-86EBF408-F95B-4F8A-827E-1DE95BCC147A

Q35889917-8C0032DE-A640-46A4-92A0-7A46DB5F8404

P2860

Q35889917-0716016A-5EC4-4915-B13B-17CDCB491FC4

Q35889917-0AE3AF09-9F75-4535-A626-65F92F0F200C

Q35889917-5C6FA0C8-C745-4A9A-B129-5B44521E9B83

Q35889917-68A096EA-2704-4ABB-82EB-5074A7FF524B

Q35889917-9113FD8E-3217-45E0-A6D0-CBFC95578CD0

Q35889917-B27A020B-BF1B-403D-83E1-2EB7202BA900

Q35889917-E21C3CF3-9425-4E8C-9465-DF31A7FE34AA

P304

Q35889917-72FC1E1C-0D7B-46F2-A781-864DED0DFA25

P31

Q35889917-AC910B5F-2E92-4C57-911B-5FFE15B03528

P356

Q35889917-A26993BB-1685-48DC-A24C-E5A690022509

P407

Q35889917-DDE14419-5C69-4A9F-B3DA-1827AD6D5D5F

P433

Q35889917-12B91324-AFA7-4DF1-BFEB-F8B0D10DAB8C

P478

Q35889917-F6DD50AF-1EC4-4BA4-9487-B503E573CF10

P50

Q35889917-030305F2-47AF-4A10-8620-415FCB1903D5

Q35889917-5E6511D0-1D49-48F5-B723-2EB6C983D3CE

Q35889917-7CEA776D-19BD-498A-AD89-64DA5BF6B502

Q35889917-86553679-C4F4-44C9-A7EC-24E8ADAF72A3

Q35889917-909221F9-5C9B-49E6-BCDF-3596BB9642FA

Q35889917-97CD969A-EA36-4269-857A-732D509C5F35

Q35889917-DC7DDA3E-6B10-4EBB-B5DE-EC06A62CB79B

Q35889917-F421E3C4-05E4-476F-A586-D170A7272094

P577

Q35889917-8182A838-9092-44E3-9C26-1C35711B3F8C

P5875

Q35889917-42001EC7-AB61-44C6-BE06-BFB7AB455C39

P698

Q35889917-749C92F3-72A7-499D-9A6F-12139DD4AECA

P921

Q35889917-233623D6-D211-44FB-9FE3-EBA89AF0B523

Q35889917-A92BC89F-0D63-4EFC-B1B0-B1DAA3CBE295

P356

P1433

Movement Disorders

P1476

Levodopa in the treatment of Parkinson's disease: current controversies.

@en

P2093

Ali H Rajput

http://www.w3.org/2001/XMLSchema#string

Catherine Mytilineou

http://www.w3.org/2001/XMLSchema#string

Christina Sampaio

http://www.w3.org/2001/XMLSchema#string

Eldad Melamed

http://www.w3.org/2001/XMLSchema#string

F Grandas

http://www.w3.org/2001/XMLSchema#string

Jose A Obeso

http://www.w3.org/2001/XMLSchema#string

Justo De Yebenes

http://www.w3.org/2001/XMLSchema#string

M A Mena

http://www.w3.org/2001/XMLSchema#string

Mark Guttman

http://www.w3.org/2001/XMLSchema#string

Ole Hornykiewicz

http://www.w3.org/2001/XMLSchema#string

P2860

Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease

Slowing Parkinson's disease progression: recent dopamine agonist trials.

Initial agonist treatment of Parkinson disease: a critique.

Agonists vs levodopa in PD: the thrilla of whitha.

Aging and the extrapyramidal system.

Chronic dopa feeding of mice.

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

P304

997-1005

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MDS.20243

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Fabrizio Stocchi

Alberto Albanese

C Warren Olanow

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8341494

http://www.w3.org/2001/XMLSchema#string

P698

15372588

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease